InSite Vision Inc

InSite Vision — Merger or Acquisition (June 2015)

17 slides from InSite Vision's merger presentation, Jun 8, 2015

  1. Slide 1: Transformational Transactions Designed to Unlock Value at QLT

    Transformational Transactions Designed to Unlock Value at QLT June 8, 2015

  2. Slide 2: Forward-Looking Statement

    2 Forward-Looking Statement Important Information For Investors And Shareholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the transactions referred to in this material,

  3. Slide 3: Transactions' Highlights

    3 Transactions’ Highlights QLT announces agreements to undertake transactions that transform the company, unlock near and long-term value for shareholders and provide multiple opportunities for liquidity for its shareholders QLT to acquire InSite Vision in an all-share transaction at an exchange rat

  4. Slide 4: New QLT at a Glance

    4 New QLT at a Glance (Through QLT’s Acquisition of InSite Vision) Late stage, diversified ophthalmic pipeline focused on front of the eye and retinal indications Multiple ophthalmology clinical assets – combination of expected low risk and high upside products Portfolio includes a pivotal-trial-rea

  5. Slide 5: Strategic Review Process

    5 Strategic Review Process

  6. Slide 6: Legacy of Value Creation and Return of Capital

    6 Legacy of Value Creation and Return of Capital 2012 2013 2014 2015 In June 2012, QLT announced the result of its 2012 Annual Meeting of Shareholders which concluded that Jason Aryeh, Stephen Sabba, Jeffrey Meckler, John Kozarich, Geoffrey Cox and John Thomas would replace six of QLT’s seven previo

  7. Slide 7: Situation Overview

    7 Situation Overview Following the termination of the agreement and plan of merger with Auxilium Pharmaceuticals, Inc. in October 2014, the Board engaged Greenhill & Co. to act as advisor to the Company and to review its strategic and business options (the “Strategic Review”). Greenhill and the Boar

  8. Slide 8: Overview of Transactions

    Overview of Transactions QUT Inc.

  9. Slide 9: Maximizing the Value of All of QLT's Assets

    9 Maximizing the Value of All of QLT’s Assets “New QLT” (QLT’s Acquisition of InSite Vision) Convertible Note to QLT / InSIte Shareholders Creates a well-capitalized, pure play ophthalmology company with a diversified pipeline of early, mid and late stage products Approximately $70 million cash bala

  10. Slide 10: QLT's Acquisition of InSite Vision

    QLT’s Acquisition of InSite Vision 10 InSite Vision is a publicly listed ophthalmic pharmaceutical company focused on developing products for unmet eye problems, including ocular infection, pain and inflammation in ocular surgery and glaucoma The acquisition creates a well-capitalized, pure-play oph

  11. Slide 11: QLT's Acquisition of InSite Vision: Key Deal Metrics

    QLT’s Acquisition of InSite Vision 11 QLT to acquire InSite Vision in an all-share transaction at an exchange ratio of 0.048 QLT will form a new, wholly-owned subsidiary, which will merge with and into InSite Key Deal Metrics InSite valuation of $23.5 million Each share of InSite will be exchanged f

  12. Slide 12: Equity Investment into Aralez Pharmaceuticals and Return of Capital

    Equity Investment into Aralez Pharmaceuticals and Return of Capital 12 Tribute Pharmaceuticals is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets Pozen is a NASDAQ-listed pharmaceut

  13. Slide 13: Equity Investment into Aralez Pharmaceuticals and Return of Capital

    Equity Investment into Aralez Pharmaceuticals and Return of Capital 13 The transaction creates a commercial-stage specialty pharmaceutical company with the following attributes: NASDAQ and TSX listed Irish-domiciled with an optimized tax structure Capitalized with sufficient funding expected for a s

  14. Slide 14: Equity Investment into Aralez Pharmaceuticals and Return of Capital

    Equity Investment into Aralez Pharmaceuticals and Return of Capital 14 All-share merger between Tribute and Pozen and simultaneous investment from QLT and four additional new investors Aralez Pharmaceuticals QLT and new investor equity investment of $75 million in return for common shares in Aralez

  15. Slide 15: Convertible Note to QLT / InSite Shareholders and Return of Capital

    Convertible Note to QLT / InSite Shareholders and Return of Capital 15 QLT intends to issue to QLT shareholders $25 million of redeemable notes, convertible into shares of QLT Provides the opportunity to return additional capital to shareholders who are interested in near-term liquidity Alternativel

  16. Slide 16: Increased Liquidity

    17 Increased Liquidity Provides QLT shareholders with significant ownership stakes in two publicly traded companies that are positioned to provide future growth QLT / InSite will have a broad investor base and a more diverse combination of ophthalmology assets Aralez Pharmaceuticals will create a ta

  17. Slide 17: Transactions' Highlights

    18 Transactions’ Highlights QLT announces agreements to undertake transactions that transform the company, unlock near and long-term value for shareholders and provide multiple opportunities for liquidity for its shareholders QLT to acquire InSite Vision in an all-share transaction at an exchange ra

Insite Vision — Merger or Acquisition (June 2015) on 6ix